| Net sales | 654.01M |
| Cost of goods sold | 415.04M |
| Gross profit | 238.97M |
| Selling, general and administrative expenses | 86.3M |
| Research and development expenses | 21.01M |
| Restructuring and other charges | |
| Operating profit | 124.91M |
| Interest and financing expenses | -15.95M |
| Other (expenses) income, net | 2.99M |
| Income before income taxes and equity in net income of unconsolidated investments | 111.95M |
| Income tax expense | 12.39M |
| Income before equity in net income of unconsolidated investments | 99.56M |
| Equity in net income of unconsolidated investments (net of tax) | 14.95M |
| Net income | 137.7M |
| Net income attributable to noncontrolling interests | -9.48M |
| Net income attributable to Albemarle Corporation | 128.22M |
| Basic earnings per share | 1.14 |
| Diluted earnings per share | 1.13 |
| Weighted-average common shares outstanding - basic | 112.43M |
| Weighted-average common shares outstanding - diluted | 113.45M |
| Cash dividends declared per share of common stock | 0.31 |